Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
Abstract The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning thes...
Main Authors: | Hetty E. Carraway, Sridhar A. Malkaram, Yana Cen, Aymen Shatnawi, Jun Fan, Hamdy E. A. Ali, Zakaria Y. Abd Elmageed, Thomm Buttolph, James Denvir, Donald A. Primerano, Tamer E. Fandy |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2020-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-67170-8 |
Similar Items
-
The genome-wide mutational consequences of DNA hypomethylation
by: Nicolle Besselink, et al.
Published: (2023-04-01) -
Emerging therapies for acute myeloid leukemia
by: Caner Saygin, et al.
Published: (2017-04-01) -
Substrate-Dependent Sensitivity of SIRT1 to Nicotinamide Inhibition
by: Stacia Rymarchyk, et al.
Published: (2021-02-01) -
The Link Between Hyperhomocysteinemia and Hypomethylation
by: Madalena Barroso PhD, et al.
Published: (2017-04-01) -
Activation of SIRT6 Deacetylation by DNA Strand Breaks
by: Wenjia Kang, et al.
Published: (2023-10-01)